AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04451681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiopulmonary exercise test
Description: Data such as oxygen consumption, cardiac parameters and speed of the patient are analyzed numerically on the treadmill in the KPET; Objective performance values such as maximum oxygen use (VO2max), maximum heart rate, respiratory capacity, and maximum rate will be obtained.
Study NCT05274321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanodropper
Description: Device used for administering eye drops
Study NCT05274321 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Eye Dropper
Description: Standard Eye Dropper used for administering eye drops
Study NCT04856423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The us-qFIT and colonoscopy with pathological examination
Description: Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
Study NCT06007911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level -1
Description: 25 mg by mouth on days 1-7.
Study NCT06007911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 0
Description: 50 mg by mouth on days 1-10.
Study NCT06007911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 1
Description: 75 mg by mouth on days 1-10.
Study NCT05756205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR)
Description: The intervention will consist of an Immersive Virtual Reality (IVR) application with virtual reality goggles Oculus GO, to reduce anxiety during pregnancy. This application lasts 14 minutes by the use of mindfulness techniques based on breathing, mindfulness and passive muscle relaxation. It consists of three modules that can be chosen completely or separately.~The aspects that conform this intervention will be: information about, the most common perinatal mental health problems, exercises based on attention to breathing (mindfulness-relaxation), 6 weeks of duration, for 14 minutes a day, knowledge from involved personnel of the number of times the woman has connected and the time she has done the exercise, satisfaction questions to pregnant women after pregnancy, alerts to notify the principal investigator if there is a problem with e-health, and, finally, an email address to contact the principal investigator.
Study NCT06388460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Link
Description: Providers enroll patients to receive school-supervised asthma therapy and an asthma educational workbook
Study NCT06388460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Providers enroll patients to receive an asthma educational workbook
Study NCT05526092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Changes in metabolism, microbiota, vitality and comprehensive health after 6 week consumption of oat / rice.
Study NCT05526092 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary intervention
Description: Changes in metabolism, microbiota, vitality and comprehensive health after 6 week consumption of oat / rice.
Study NCT05291741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VLCD
Description: Advice regarding VLCD
Study NCT05291741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard dietary advice for weight loss before bariatric surgery
Study NCT05122013 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A comprehensive remote multidisciplinary intervention for weight regain after sleeve gastrectomy
Description: A remote 3-months multidisciplinary intervention for weight regain after sleeve gastrectomy including bi-monthly remote consultations with a registered dietitian, physical activity consultant and sleep consultant, combined with weekly text messages meant to enhance happiness and subjective wellbeing.
Study NCT05122013 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: Standard nutritional care: One frontal meeting with the study's registered dietitian at the clinic, including nutritional and behavioral assessment and recommendations, followed by guidance to to continue follow up in order to support healthy lifestyle.
Study NCT06007911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 2
Description: 100 mg by mouth on days 1-10.
Study NCT05368571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHOICES-TEEN
Description: This is a four-session hybrid in-person and Telehealth counseling intervention that is designed to reduce the risk of HIV/STI and alcohol- and marijuana-exposed pregnancy for young women who are involved in the juvenile justice system between the ages of 14-19.
Study NCT05368571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health and Life Skills Education
Description: This is a four-session psychoeducational intervention that is designed to provide information on time management, sleep, nutrition and exercise, and financial management.
Study NCT05239923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis
Description: Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
Study NCT06302868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine Exposure Therapy Using Photos and Videos
Description: Participants will complete 12 60-minute exposure therapy sessions using photos/videos and progress to in vivo exposures.
Study NCT06302868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine-Based Virtual Reality Exposure Therapy
Description: Participants will complete 12 60-minute exposure therapy sessions in a Virtual Reality Clinic using Virtual Reality stimuli and progress to in vivo exposures.
Study NCT05657080 — intervention group
Intervention type: DEVICE
Intervention: Cytosponge-TFF3
Description: Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.
Study NCT06007911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Level -1
Description: 400 mg by mouth on days 1-7.
Study NCT06007911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Levels 0 to 2
Description: 400 mg by mouth on days 1-14.
Study NCT06007911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5 mg/m\^2 intravenously days 1-5.
Study NCT04964505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT04964505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Given IV
Study NCT04964505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04757480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracolumbar Interfascial Plane Block (TLIP)
Description: (20ml) (plain bupivacaine 0.25% on each side toward the LG-MF interface.
Study NCT04772911 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: OCT will be performed at baseline and prior to each standard of care laser treatment to characterize the mean diameter and depth of blood vessels.
Study NCT04962204 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual meeting between patients/physicians and caregiver
Description: Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day
Study NCT05333978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSOT Device
Description: The MSOT Device will be used to take images of the areas of inflammation in patients with inflammatory diseases such as GVHD, Colitis, and IBD, prior to, and after 4 weeks of treatment.
Study NCT05333978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature Measurement
Description: The temperature of the skin will be measured prior to and after each instance of MSOT imaging.
Study NCT06342414 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELUCIDATE
Description: ELUCIDATE (Evaluation of Liver Cholangiocarcinoma Intrahepatic)
Study NCT06301685 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine therapy
Description: The study lasts 10 days for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
Study NCT06301685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine therapy
Description: The study lasts 10 days for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
Study NCT06301685 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT00012805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Telephone Monitoring
Study NCT06301685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06301685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. once a day.
Study NCT05664971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection
Description: 200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
Study NCT04835441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPN-101
Description: Blinded ALPN-101 will be administered
Study NCT04835441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded placebo matching ALPN-101 will be administered.
Study NCT04739917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine PvCS N+C+R 150 mcg
Description: Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.
Study NCT04739917 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SSN Montanide ISA-51 1 mL
Description: SSN Montanide ISA-51 1 mL
Study NCT04940741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)
Study NCT04940741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator without active ingredient
Study NCT05664971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
Study NCT06191016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagal nerve stimulation
Description: Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications
Study NCT06191016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation
Description: Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications
Study NCT06191016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham vagal nerve stimulation
Description: control will receive sham stimulation to vagal nerve along with prescribed medications
Study NCT06191016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham vagal nerve stimulation
Description: control will receive sham stimulation to vagal nerve along with prescribed medications
Study NCT06007911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Cladribine Low Dose Cytarabine Backbone)
Description: 20 mg/m\^2 subcutaneous days 1-10.
Study NCT06007911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (CLAG-M Backbone)
Description: 1.5 g/m\^2 intravenously days 1-5.
Study NCT06007911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m\^2 intravenously days 1-3.
Study NCT06007911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 300 mcg subcutaneously days 1-5.
Study NCT05664971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 or 75mg/m2 via IV infusion on Day 1 of a 21-day cycle, which may be maintained until disease progression
Study NCT05664971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles; Subjects who have disease progression after 4 cycles may continue to receive maintenance treatment with pemetrexed
Study NCT05664971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
Study NCT05664971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
Study NCT05664971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
Study NCT05664971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m2 via IV infusion on Days 1, 2, and 3 of a 21-day cycle for 4 cycles
Study NCT06485882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Training
Description: Animation films are watched children about self-care and social competence
Study NCT05134012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [O-15]-Water PET Myocardial Perfusion Imaging (MPI)
Description: \[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
Study NCT05124613 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Information collected and stored in Survey:~* Type of knee surgery the patient is waitlisted for~* Demographics: age, sex, recent weight gain~* Validated and bespoke questions:~  1. EQ-5D survey (a validated questionnaire on health)~ 2. Bespoke questions on knee pain today~ 3. Bespoke questions on knee function today~ 4. Bespoke questions on change in knee pain since being waitlisted for surgery~ 5. Bespoke questions on change in knee function since being waitlisted for surgery~ 6. Bespoke questions on coping mechanisms patients use to manage symptoms~ 7. Bespoke questions on what support they would find beneficial whilst they wait for their surgery~ 8. Three bespoke questions about COVID-19 (Have they ever tested positive/Has the pandemic changed their mind about wanting surgery/Has the perception of their knee pain and function changed since the first lockdown was introduced?)
Study NCT04738201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive thumb exercises.
Description: Exercises for recognition of thumb position and thumb force sense.
Study NCT04781998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide 3 mg (Saxenda®) once-daily
Description: Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.
Study NCT05224752 — intervention group
Intervention type: OTHER
Intervention: Online Survey
Description: Online survey void of individual traceable identifiers, and launched via the Survey Monkey® portal
Study NCT04708340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rejuveinix (RJX) Active Comparator
Description: Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and sodium bicarbonate.
Study NCT04708340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 0.9% Sodium Chloride in Water for Injection a.k.a. Normal Saline for injection
Study NCT04738201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive thumb exercises.
Description: Exercises for recognition of thumb position and thumb force sense.
Study NCT06049940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational tetanus vaccine, adsorbed
Description: The investigational vaccine was manufactured by Sinovac Life Sciences Co., Ltd. There is not less than 40IU tetanus toxoid in 0.5ml per dose.
Study NCT06049940 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control tetanus vaccine, adsorbed
Description: The control tetanus vaccine, adsorbed was manufactured by Chengdu Olymvax Biopharmaceuticals Inc.There is not less than 40IU tetanus toxoid in 0.5ml per dose.
Study NCT04757480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Erector Spinae plane Block (ESB)
Description: Will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the eighth thoracic segment (T8).
Study NCT05352321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: for induction chemotherapy
Study NCT05352321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: for induction chemotherapy
Study NCT05352321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: for induction and concurrent chemotherapy
Study NCT05352321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: for induction and concurrent chemotherapy
Study NCT05352321 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: regular intensity-modulated radiotherapy
Description: in active comparator arm
Study NCT05352321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: in experimental arm
Study NCT05352321 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Target-reduction intensity-modulated radiotherapy
Description: in experimental arm
Study NCT06516146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention will involve online (via University of British Colombia (UBC) Zoom videoconferencing) 1-hour moderate to high intensity exercise classes 3 times a week for 6 months